Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Express Scripts
McKinsey
AstraZeneca
Colorcon
McKesson
Harvard Business School

Last Updated: June 27, 2022

Actelion Company Profile


✉ Email this page to a colleague

« Back to Dashboard

Summary for Actelion
International Patents:245
US Patents:15
Tradenames:6
Ingredients:6
NDAs:8
PTAB Cases with Actelion as petitioner: See PTAB cases with Actelion as petitioner

Drugs and US Patents for Actelion

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actelion VELETRI epoprostenol sodium INJECTABLE;INJECTION 022260-002 Jun 28, 2012 AP2 RX Yes Yes 8,598,227 See Plans and Pricing See Plans and Pricing
Actelion UPTRAVI selexipag TABLET;ORAL 207947-002 Dec 21, 2015 RX Yes Yes 10,821,108 See Plans and Pricing Y See Plans and Pricing
Actelion UPTRAVI selexipag TABLET;ORAL 207947-008 Dec 21, 2015 RX Yes No 10,821,108 See Plans and Pricing Y See Plans and Pricing
Actelion UPTRAVI selexipag TABLET;ORAL 207947-003 Dec 21, 2015 RX Yes No 10,821,108 See Plans and Pricing Y See Plans and Pricing
Actelion UPTRAVI selexipag TABLET;ORAL 207947-007 Dec 21, 2015 RX Yes No 10,821,108 See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Actelion

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Actelion TRACLEER bosentan TABLET;ORAL 021290-002 Nov 20, 2001 5,292,740 See Plans and Pricing
Actelion ZAVESCA miglustat CAPSULE;ORAL 021348-001 Jul 31, 2003 5,472,969 See Plans and Pricing
Actelion TRACLEER bosentan TABLET;ORAL 021290-001 Nov 20, 2001 5,292,740 See Plans and Pricing
Actelion ZAVESCA miglustat CAPSULE;ORAL 021348-001 Jul 31, 2003 5,525,616 See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for ACTELION drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe for Oral Suspension 32 mg ➤ Subscribe 2019-02-08
➤ Subscribe Tablets 10 mg ➤ Subscribe 2017-10-18

Supplementary Protection Certificates for Actelion Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1345920 92381 Luxembourg See Plans and Pricing PRODUCT NAME: MACITENTAN ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES(OPSUMIT)
2447254 PA2018008,C2447254 Lithuania See Plans and Pricing PRODUCT NAME: SELEKSIPAGAS; REGISTRATION NO/DATE: EU/1/15/1083 20160512
1345920 2014C/019 Belgium See Plans and Pricing PRODUCT NAME: MACITENTAN ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/13/893 20131227
1345920 300672 Netherlands See Plans and Pricing PRODUCT NAME: MACITENTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/13/893/001-003 20131220
1345920 1490025-2 Sweden See Plans and Pricing PRODUCT NAME: MACITENTAN; REG. NO/DATE: EU/1/13/893 20131220
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Mallinckrodt
Colorcon
Express Scripts
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.